Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
OSA - ProSomnus, Inc.
Market Cap 34.15M P/E - EPS this Y - Ern Qtrly Grth -
Income -24.09M Forward P/E -2.61 EPS next Y 22.00% 50D Avg Chg -40.00%
Sales 27.65M PEG - EPS past 5Y - 200D Avg Chg -63.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -82.00%
Recommedations 2.00 Quick Ratio 0.71 Shares Outstanding 17.39M 52W Low Chg 9.00%
Insider Own 20.64% ROA -40.15% Shares Float 8.09M Beta 0.21
Inst Own 57.01% ROE - Shares Shorted/Prior 73.91K/152.97K Price 2.09
Gross Margin 50.67% Profit Margin -87.14% Avg. Volume 13,595 Target Price 2.50
Oper. Margin -63.92% Earnings Date - Volume 3,294 Change -0.24%
Healthcare | Medical Devices | United States
About ProSomnus, Inc.

ProSomnus, Inc. operates as a medical technology company that develops, manufactures, and markets precision intraoral medical devices for treating and managing patients with obstructive sleep apnea. The company sells its products to sleep dentists, sleep physicians, primary care providers, otolaryngologists, and other integrated healthcare service providers through a direct sales force. ProSomnus, Inc. is headquartered in Pleasanton, California.

ProSomnus, Inc. News
03/30/24 ProSomnus, Inc. Common Stock (NASDAQ:OSA) Q4 2023 Earnings Call Transcript
03/26/24 ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results
03/15/24 ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call
02/22/24 ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
02/20/24 ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024
01/30/24 ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
01/29/24 ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
01/08/24 ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea
12/19/23 ProSomnus Treatment for Sleep Apnea Effective, Study Shows
12/19/23 Data Published by Cureus Journal of Medical Science Shows Successful Treatment of Obstructive Sleep Apnea with ProSomnus Precision Oral Appliance Devices
12/12/23 ProSomnus CEO Len Liptak unveils game-changing device and promising clinical trial results for 2024
11/09/23 ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results
10/31/23 ProSomnus Announces Third Quarter 2023 Investor Call and Business Update
10/03/23 ProSomnus Announces Participation in the 2023 Roth Capital Healthcare Opportunities Conference
09/21/23 ProSomnus Secures $10 Million to Drive Growth
09/21/23 ProSomnus Raises $10 Million To Fuel Growth and Optimize Operations
09/14/23 ProSomnus Showcasing Sleep Apnea Treatment at Medical Conferences
09/14/23 ProSomnus Precision Obstructive Sleep Apnea Devices to be Featured in Scientific Abstracts and Podium Presentations at Upcoming Medical Conferences
08/23/23 ProSomnus Updated Clinical Trial Data Indicates Therapy is Non-Inferior to CPAP
08/23/23 Updated Clinical Trial Data Indicates Precision Oral Appliance Therapy with ProSomnus Devices is Non-Inferior to CPAP Therapy for the Treatment of Moderate to Severe Obstructive Sleep Apnea